デュシェンヌ型筋ジストロフィー薬の世界市場（～2026年）

• 英文タイトル：Global Duchenne Muscular Dystrophy Drugs Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY05476 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、185ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料はデュシェンヌ型筋ジストロフィー薬のグローバル市場について調査・分析したレポートです。種類別（開発・創薬ターゲット、作用機序（MoA）、投与経路（RoA）、分子タイプ）市場規模、用途別（病院・診療所、臨床検査室、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別デュシェンヌ型筋ジストロフィー薬の競争状況、市場シェア ・世界のデュシェンヌ型筋ジストロフィー薬市場：種類別市場規模 2015年-2020年（開発・創薬ターゲット、作用機序（MoA）、投与経路（RoA）、分子タイプ） ・世界のデュシェンヌ型筋ジストロフィー薬市場：種類別市場規模予測 2021年-2026年（開発・創薬ターゲット、作用機序（MoA）、投与経路（RoA）、分子タイプ） ・世界のデュシェンヌ型筋ジストロフィー薬市場：用途別市場規模 2015年-2020年（病院・診療所、臨床検査室、その他） ・世界のデュシェンヌ型筋ジストロフィー薬市場：用途別市場規模予測 2021年-2026年（病院・診療所、臨床検査室、その他） ・北米のデュシェンヌ型筋ジストロフィー薬市場分析：米国、カナダ ・ヨーロッパのデュシェンヌ型筋ジストロフィー薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのデュシェンヌ型筋ジストロフィー薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のデュシェンヌ型筋ジストロフィー薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのデュシェンヌ型筋ジストロフィー薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Akashi Therapeutics Inc、Antisense Therapeutics Ltd、Beech Tree Labs Inc、Biogen Inc、Bioleaders Corp、BioMarin Pharmaceutical Inc、Biophytis SAS、Capricor Therapeutics Inc、Catabasis Pharmaceuticals Inc、CRISPR Therapeutics、Cumberland Pharmaceuticals Inc、Daiichi Sankyo Co Ltd、Debiopharm International SA、Editas Medicine Inc、Eloxx Pharmaceuticals Inc、F. Hoffmann-La Roche Ltd、FibroGen Inc、Fulcrum Therapeutics Inc、Galapagos NV、Genethon SA、GTx Inc、Santhera Pharmaceuticals Holding AG、Sarepta Therapeutics Inc、SOM Biotech SL、Strykagen Corp、Summit Therapeutics Plc、Taiho Pharmaceutical Co Ltd、Teijin Pharma Ltd、WAVE Life Sciences Ltd ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essential for maintaining healthy muscle function) in individuals. The lack of dystrophin weakens muscle function, causes loss of ambulation, harms the respiratory and cardiac function, and ultimately leads to death.
The main symptoms of this condition appears in childhood and includes delay of motor functions; progressive muscle weakness; muscle contractures in legs; and muscle weakness in arms, neck, and more severely in the lower half of the body. The bones also develop peculiarly, causing skeletal deformities in the patient. Occurrences of pseudo-hypertrophy, cardiomyopathy, and breathing complications are some of the other symptoms of this condition.

Market Analysis and Insights: Global Duchenne Muscular Dystrophy Drugs Market
The global Duchenne Muscular Dystrophy Drugs market size is projected to reach US$ 1262.2 million by 2026, from US$ 961.9 million in 2020, at a CAGR of 28.9%% during 2021-2026.

Global Duchenne Muscular Dystrophy Drugs Scope and Market Size
Duchenne Muscular Dystrophy Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Duchenne Muscular Dystrophy Drugs market is segmented into
Development & Drug Target
Mechanism of Action (MoA)
Route of Administration (RoA)
Molecule Type

Segment by Application, the Duchenne Muscular Dystrophy Drugs market is segmented into
Hospitals and Clinics
Medical Laboratories
Others

Regional and Country-level Analysis
The Duchenne Muscular Dystrophy Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Duchenne Muscular Dystrophy Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Duchenne Muscular Dystrophy Drugs Market Share Analysis
Duchenne Muscular Dystrophy Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Duchenne Muscular Dystrophy Drugs business, the date to enter into the Duchenne Muscular Dystrophy Drugs market, Duchenne Muscular Dystrophy Drugs product introduction, recent developments, etc.

The major vendors covered:
Akashi Therapeutics Inc
Antisense Therapeutics Ltd
Beech Tree Labs Inc
Biogen Inc
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SAS
Capricor Therapeutics Inc
Catabasis Pharmaceuticals Inc
CRISPR Therapeutics
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
FibroGen Inc
Fulcrum Therapeutics Inc
Galapagos NV
Genethon SA
GTx Inc
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics Inc
SOM Biotech SL
Strykagen Corp
Summit Therapeutics Plc
Taiho Pharmaceutical Co Ltd
Teijin Pharma Ltd
WAVE Life Sciences Ltd

レポート目次

---

1 Study Coverage
1.1 Duchenne Muscular Dystrophy Drugs Product Introduction
1.2 Market Segments
1.3 Key Duchenne Muscular Dystrophy Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type
1.4.2 Development & Drug Target
1.4.3 Mechanism of Action (MoA)
1.4.4 Route of Administration (RoA)
1.4.5 Molecule Type
1.5 Market by Application
1.5.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Application
1.5.2 Hospitals and Clinics
1.5.3 Medical Laboratories
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Duchenne Muscular Dystrophy Drugs Market Size, Estimates and Forecasts
2.1.1 Global Duchenne Muscular Dystrophy Drugs Revenue 2015-2026
2.1.2 Global Duchenne Muscular Dystrophy Drugs Sales 2015-2026
2.2 Global Duchenne Muscular Dystrophy Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Duchenne Muscular Dystrophy Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Duchenne Muscular Dystrophy Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Duchenne Muscular Dystrophy Drugs Competitor Landscape by Players
3.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers
3.1.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers (2015-2020)
3.1.2 Duchenne Muscular Dystrophy Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers
3.2.1 Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Drugs Revenue in 2019
3.2.5 Global Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Duchenne Muscular Dystrophy Drugs Price by Manufacturers
3.4 Duchenne Muscular Dystrophy Drugs Manufacturing Base Distribution, Product Types
3.4.1 Duchenne Muscular Dystrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Duchenne Muscular Dystrophy Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2015-2020)
4.1.1 Global Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020)
4.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Type (2015-2020)
4.1.3 Duchenne Muscular Dystrophy Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Duchenne Muscular Dystrophy Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Duchenne Muscular Dystrophy Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2015-2020)
5.1.1 Global Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020)
5.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Application (2015-2020)
5.1.3 Duchenne Muscular Dystrophy Drugs Price by Application (2015-2020)
5.2 Duchenne Muscular Dystrophy Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Duchenne Muscular Dystrophy Drugs Price Forecast by Application (2021-2026)

6 North America
6.1 North America Duchenne Muscular Dystrophy Drugs by Country
6.1.1 North America Duchenne Muscular Dystrophy Drugs Sales by Country
6.1.2 North America Duchenne Muscular Dystrophy Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
6.3 North America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application

7 Europe
7.1 Europe Duchenne Muscular Dystrophy Drugs by Country
7.1.1 Europe Duchenne Muscular Dystrophy Drugs Sales by Country
7.1.2 Europe Duchenne Muscular Dystrophy Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
7.3 Europe Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Duchenne Muscular Dystrophy Drugs by Region
8.1.1 Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Region
8.1.2 Asia Pacific Duchenne Muscular Dystrophy Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
8.3 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application

9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy Drugs by Country
9.1.1 Latin America Duchenne Muscular Dystrophy Drugs Sales by Country
9.1.2 Latin America Duchenne Muscular Dystrophy Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
9.3 Central & South America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs by Country
10.1.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Country
10.1.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application

11 Company Profiles
11.1 Akashi Therapeutics Inc
11.1.1 Akashi Therapeutics Inc Corporation Information
11.1.2 Akashi Therapeutics Inc Description and Business Overview
11.1.3 Akashi Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.1.5 Akashi Therapeutics Inc Related Developments
11.2 Antisense Therapeutics Ltd
11.2.1 Antisense Therapeutics Ltd Corporation Information
11.2.2 Antisense Therapeutics Ltd Description and Business Overview
11.2.3 Antisense Therapeutics Ltd Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Products Offered
11.2.5 Antisense Therapeutics Ltd Related Developments
11.3 Beech Tree Labs Inc
11.3.1 Beech Tree Labs Inc Corporation Information
11.3.2 Beech Tree Labs Inc Description and Business Overview
11.3.3 Beech Tree Labs Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.3.5 Beech Tree Labs Inc Related Developments
11.4 Biogen Inc
11.4.1 Biogen Inc Corporation Information
11.4.2 Biogen Inc Description and Business Overview
11.4.3 Biogen Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Biogen Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.4.5 Biogen Inc Related Developments
11.5 Bioleaders Corp
11.5.1 Bioleaders Corp Corporation Information
11.5.2 Bioleaders Corp Description and Business Overview
11.5.3 Bioleaders Corp Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Products Offered
11.5.5 Bioleaders Corp Related Developments
11.6 BioMarin Pharmaceutical Inc
11.6.1 BioMarin Pharmaceutical Inc Corporation Information
11.6.2 BioMarin Pharmaceutical Inc Description and Business Overview
11.6.3 BioMarin Pharmaceutical Inc Sales, Revenue and Gross Margin (2015-2020)
11.6.4 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.6.5 BioMarin Pharmaceutical Inc Related Developments
11.7 Biophytis SAS
11.7.1 Biophytis SAS Corporation Information
11.7.2 Biophytis SAS Description and Business Overview
11.7.3 Biophytis SAS Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Biophytis SAS Duchenne Muscular Dystrophy Drugs Products Offered
11.7.5 Biophytis SAS Related Developments
11.8 Capricor Therapeutics Inc
11.8.1 Capricor Therapeutics Inc Corporation Information
11.8.2 Capricor Therapeutics Inc Description and Business Overview
11.8.3 Capricor Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.8.5 Capricor Therapeutics Inc Related Developments
11.9 Catabasis Pharmaceuticals Inc
11.9.1 Catabasis Pharmaceuticals Inc Corporation Information
11.9.2 Catabasis Pharmaceuticals Inc Description and Business Overview
11.9.3 Catabasis Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.9.5 Catabasis Pharmaceuticals Inc Related Developments
11.10 CRISPR Therapeutics
11.10.1 CRISPR Therapeutics Corporation Information
11.10.2 CRISPR Therapeutics Description and Business Overview
11.10.3 CRISPR Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.10.4 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Products Offered
11.10.5 CRISPR Therapeutics Related Developments
11.1 Akashi Therapeutics Inc
11.1.1 Akashi Therapeutics Inc Corporation Information
11.1.2 Akashi Therapeutics Inc Description and Business Overview
11.1.3 Akashi Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered
11.1.5 Akashi Therapeutics Inc Related Developments
11.12 Daiichi Sankyo Co Ltd
11.12.1 Daiichi Sankyo Co Ltd Corporation Information
11.12.2 Daiichi Sankyo Co Ltd Description and Business Overview
11.12.3 Daiichi Sankyo Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Daiichi Sankyo Co Ltd Products Offered
11.12.5 Daiichi Sankyo Co Ltd Related Developments
11.13 Debiopharm International SA
11.13.1 Debiopharm International SA Corporation Information
11.13.2 Debiopharm International SA Description and Business Overview
11.13.3 Debiopharm International SA Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Debiopharm International SA Products Offered
11.13.5 Debiopharm International SA Related Developments
11.14 Editas Medicine Inc
11.14.1 Editas Medicine Inc Corporation Information
11.14.2 Editas Medicine Inc Description and Business Overview
11.14.3 Editas Medicine Inc Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Editas Medicine Inc Products Offered
11.14.5 Editas Medicine Inc Related Developments
11.15 Eloxx Pharmaceuticals Inc
11.15.1 Eloxx Pharmaceuticals Inc Corporation Information
11.15.2 Eloxx Pharmaceuticals Inc Description and Business Overview
11.15.3 Eloxx Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Eloxx Pharmaceuticals Inc Products Offered
11.15.5 Eloxx Pharmaceuticals Inc Related Developments
11.16 F. Hoffmann-La Roche Ltd
11.16.1 F. Hoffmann-La Roche Ltd Corporation Information
11.16.2 F. Hoffmann-La Roche Ltd Description and Business Overview
11.16.3 F. Hoffmann-La Roche Ltd Sales, Revenue and Gross Margin (2015-2020)
11.16.4 F. Hoffmann-La Roche Ltd Products Offered
11.16.5 F. Hoffmann-La Roche Ltd Related Developments
11.17 FibroGen Inc
11.17.1 FibroGen Inc Corporation Information
11.17.2 FibroGen Inc Description and Business Overview
11.17.3 FibroGen Inc Sales, Revenue and Gross Margin (2015-2020)
11.17.4 FibroGen Inc Products Offered
11.17.5 FibroGen Inc Related Developments
11.18 Fulcrum Therapeutics Inc
11.18.1 Fulcrum Therapeutics Inc Corporation Information
11.18.2 Fulcrum Therapeutics Inc Description and Business Overview
11.18.3 Fulcrum Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Fulcrum Therapeutics Inc Products Offered
11.18.5 Fulcrum Therapeutics Inc Related Developments
11.19 Galapagos NV
11.19.1 Galapagos NV Corporation Information
11.19.2 Galapagos NV Description and Business Overview
11.19.3 Galapagos NV Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Galapagos NV Products Offered
11.19.5 Galapagos NV Related Developments
11.20 Genethon SA
11.20.1 Genethon SA Corporation Information
11.20.2 Genethon SA Description and Business Overview
11.20.3 Genethon SA Sales, Revenue and Gross Margin (2015-2020)
11.20.4 Genethon SA Products Offered
11.20.5 Genethon SA Related Developments
11.21 GTx Inc
11.21.1 GTx Inc Corporation Information
11.21.2 GTx Inc Description and Business Overview
11.21.3 GTx Inc Sales, Revenue and Gross Margin (2015-2020)
11.21.4 GTx Inc Products Offered
11.21.5 GTx Inc Related Developments
11.22 Santhera Pharmaceuticals Holding AG
11.22.1 Santhera Pharmaceuticals Holding AG Corporation Information
11.22.2 Santhera Pharmaceuticals Holding AG Description and Business Overview
11.22.3 Santhera Pharmaceuticals Holding AG Sales, Revenue and Gross Margin (2015-2020)
11.22.4 Santhera Pharmaceuticals Holding AG Products Offered
11.22.5 Santhera Pharmaceuticals Holding AG Related Developments
11.23 Sarepta Therapeutics Inc
11.23.1 Sarepta Therapeutics Inc Corporation Information
11.23.2 Sarepta Therapeutics Inc Description and Business Overview
11.23.3 Sarepta Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.23.4 Sarepta Therapeutics Inc Products Offered
11.23.5 Sarepta Therapeutics Inc Related Developments
11.24 SOM Biotech SL
11.24.1 SOM Biotech SL Corporation Information
11.24.2 SOM Biotech SL Description and Business Overview
11.24.3 SOM Biotech SL Sales, Revenue and Gross Margin (2015-2020)
11.24.4 SOM Biotech SL Products Offered
11.24.5 SOM Biotech SL Related Developments
11.25 Strykagen Corp
11.25.1 Strykagen Corp Corporation Information
11.25.2 Strykagen Corp Description and Business Overview
11.25.3 Strykagen Corp Sales, Revenue and Gross Margin (2015-2020)
11.25.4 Strykagen Corp Products Offered
11.25.5 Strykagen Corp Related Developments
11.26 Summit Therapeutics Plc
11.26.1 Summit Therapeutics Plc Corporation Information
11.26.2 Summit Therapeutics Plc Description and Business Overview
11.26.3 Summit Therapeutics Plc Sales, Revenue and Gross Margin (2015-2020)
11.26.4 Summit Therapeutics Plc Products Offered
11.26.5 Summit Therapeutics Plc Related Developments
11.27 Taiho Pharmaceutical Co Ltd
11.27.1 Taiho Pharmaceutical Co Ltd Corporation Information
11.27.2 Taiho Pharmaceutical Co Ltd Description and Business Overview
11.27.3 Taiho Pharmaceutical Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.27.4 Taiho Pharmaceutical Co Ltd Products Offered
11.27.5 Taiho Pharmaceutical Co Ltd Related Developments
11.28 Teijin Pharma Ltd
11.28.1 Teijin Pharma Ltd Corporation Information
11.28.2 Teijin Pharma Ltd Description and Business Overview
11.28.3 Teijin Pharma Ltd Sales, Revenue and Gross Margin (2015-2020)
11.28.4 Teijin Pharma Ltd Products Offered
11.28.5 Teijin Pharma Ltd Related Developments
11.29 WAVE Life Sciences Ltd
11.29.1 WAVE Life Sciences Ltd Corporation Information
11.29.2 WAVE Life Sciences Ltd Description and Business Overview
11.29.3 WAVE Life Sciences Ltd Sales, Revenue and Gross Margin (2015-2020)
11.29.4 WAVE Life Sciences Ltd Products Offered
11.29.5 WAVE Life Sciences Ltd Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Duchenne Muscular Dystrophy Drugs Market Estimates and Projections by Region
12.1.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
12.2.2 North America: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Duchenne Muscular Dystrophy Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Duchenne Muscular Dystrophy Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Duchenne Muscular Dystrophy Drugs Market Segments
Table 2. Ranking of Global Top Duchenne Muscular Dystrophy Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Development & Drug Target
Table 5. Major Manufacturers of Mechanism of Action (MoA)
Table 6. Major Manufacturers of Route of Administration (RoA)
Table 7. Major Manufacturers of Molecule Type
Table 8. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 9. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 10. Global Duchenne Muscular Dystrophy Drugs Sales by Regions 2015-2020 (K Units)
Table 11. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Duchenne Muscular Dystrophy Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Duchenne Muscular Dystrophy Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 14. Global Duchenne Muscular Dystrophy Drugs Sales Share by Manufacturers (2015-2020)
Table 15. Global Duchenne Muscular Dystrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Duchenne Muscular Dystrophy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2019)
Table 17. Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Duchenne Muscular Dystrophy Drugs Price (2015-2020) (USD/Unit)
Table 20. Duchenne Muscular Dystrophy Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Duchenne Muscular Dystrophy Drugs Product Type
Table 22. Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Drugs Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020) (K Units)
Table 25. Global Duchenne Muscular Dystrophy Drugs Sales Share by Type (2015-2020)
Table 26. Global Duchenne Muscular Dystrophy Drugs Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Type (2015-2020)
Table 28. Duchenne Muscular Dystrophy Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 29. Global Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020) (K Units)
Table 30. Global Duchenne Muscular Dystrophy Drugs Sales Share by Application (2015-2020)
Table 31. North America Duchenne Muscular Dystrophy Drugs Sales by Country (2015-2020) (K Units)
Table 32. North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Country (2015-2020)
Table 33. North America Duchenne Muscular Dystrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country (2015-2020)
Table 35. North America Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020) (K Units)
Table 36. North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2015-2020)
Table 37. North America Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020) (K Units)
Table 38. North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2015-2020)
Table 39. Europe Duchenne Muscular Dystrophy Drugs Sales by Country (2015-2020) (K Units)
Table 40. Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Country (2015-2020)
Table 41. Europe Duchenne Muscular Dystrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country (2015-2020)
Table 43. Europe Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020) (K Units)
Table 44. Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2015-2020)
Table 45. Europe Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020) (K Units)
Table 46. Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Region (2015-2020) (K Units)
Table 48. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Duchenne Muscular Dystrophy Drugs Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Duchenne Muscular Dystrophy Drugs Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020) (K Units)
Table 52. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020) (K Units)
Table 54. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2015-2020)
Table 55. Latin America Duchenne Muscular Dystrophy Drugs Sales by Country (2015-2020) (K Units)
Table 56. Latin America Duchenne Muscular Dystrophy Drugs Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Duchenne Muscular Dystrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country (2015-2020)
Table 59. Latin America Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020) (K Units)
Table 60. Latin America Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2015-2020)
Table 61. Latin America Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020) (K Units)
Table 62. Latin America Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Country (2015-2020) (K Units)
Table 64. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020) (K Units)
Table 68. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020) (K Units)
Table 70. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2015-2020)
Table 71. Akashi Therapeutics Inc Corporation Information
Table 72. Akashi Therapeutics Inc Description and Major Businesses
Table 73. Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 74. Akashi Therapeutics Inc Product
Table 75. Akashi Therapeutics Inc Recent Development
Table 76. Antisense Therapeutics Ltd Corporation Information
Table 77. Antisense Therapeutics Ltd Description and Major Businesses
Table 78. Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 79. Antisense Therapeutics Ltd Product
Table 80. Antisense Therapeutics Ltd Recent Development
Table 81. Beech Tree Labs Inc Corporation Information
Table 82. Beech Tree Labs Inc Description and Major Businesses
Table 83. Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 84. Beech Tree Labs Inc Product
Table 85. Beech Tree Labs Inc Recent Development
Table 86. Biogen Inc Corporation Information
Table 87. Biogen Inc Description and Major Businesses
Table 88. Biogen Inc Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 89. Biogen Inc Product
Table 90. Biogen Inc Recent Development
Table 91. Bioleaders Corp Corporation Information
Table 92. Bioleaders Corp Description and Major Businesses
Table 93. Bioleaders Corp Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 94. Bioleaders Corp Product
Table 95. Bioleaders Corp Recent Development
Table 96. BioMarin Pharmaceutical Inc Corporation Information
Table 97. BioMarin Pharmaceutical Inc Description and Major Businesses
Table 98. BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 99. BioMarin Pharmaceutical Inc Product
Table 100. BioMarin Pharmaceutical Inc Recent Development
Table 101. Biophytis SAS Corporation Information
Table 102. Biophytis SAS Description and Major Businesses
Table 103. Biophytis SAS Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 104. Biophytis SAS Product
Table 105. Biophytis SAS Recent Development
Table 106. Capricor Therapeutics Inc Corporation Information
Table 107. Capricor Therapeutics Inc Description and Major Businesses
Table 108. Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 109. Capricor Therapeutics Inc Product
Table 110. Capricor Therapeutics Inc Recent Development
Table 111. Catabasis Pharmaceuticals Inc Corporation Information
Table 112. Catabasis Pharmaceuticals Inc Description and Major Businesses
Table 113. Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 114. Catabasis Pharmaceuticals Inc Product
Table 115. Catabasis Pharmaceuticals Inc Recent Development
Table 116. CRISPR Therapeutics Corporation Information
Table 117. CRISPR Therapeutics Description and Major Businesses
Table 118. CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 119. CRISPR Therapeutics Product
Table 120. CRISPR Therapeutics Recent Development
Table 121. Cumberland Pharmaceuticals Inc Corporation Information
Table 122. Cumberland Pharmaceuticals Inc Description and Major Businesses
Table 123. Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 124. Cumberland Pharmaceuticals Inc Product
Table 125. Cumberland Pharmaceuticals Inc Recent Development
Table 126. Daiichi Sankyo Co Ltd Corporation Information
Table 127. Daiichi Sankyo Co Ltd Description and Major Businesses
Table 128. Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 129. Daiichi Sankyo Co Ltd Product
Table 130. Daiichi Sankyo Co Ltd Recent Development
Table 131. Debiopharm International SA Corporation Information
Table 132. Debiopharm International SA Description and Major Businesses
Table 133. Debiopharm International SA Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 134. Debiopharm International SA Product
Table 135. Debiopharm International SA Recent Development
Table 136. Editas Medicine Inc Corporation Information
Table 137. Editas Medicine Inc Description and Major Businesses
Table 138. Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 139. Editas Medicine Inc Product
Table 140. Editas Medicine Inc Recent Development
Table 141. Eloxx Pharmaceuticals Inc Corporation Information
Table 142. Eloxx Pharmaceuticals Inc Description and Major Businesses
Table 143. Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 144. Eloxx Pharmaceuticals Inc Product
Table 145. Eloxx Pharmaceuticals Inc Recent Development
Table 146. F. Hoffmann-La Roche Ltd Corporation Information
Table 147. F. Hoffmann-La Roche Ltd Description and Major Businesses
Table 148. F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 149. F. Hoffmann-La Roche Ltd Product
Table 150. F. Hoffmann-La Roche Ltd Recent Development
Table 151. FibroGen Inc Corporation Information
Table 152. FibroGen Inc Description and Major Businesses
Table 153. FibroGen Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 154. FibroGen Inc Product
Table 155. FibroGen Inc Recent Development
Table 156. Fulcrum Therapeutics Inc Corporation Information
Table 157. Fulcrum Therapeutics Inc Description and Major Businesses
Table 158. Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 159. Fulcrum Therapeutics Inc Product
Table 160. Fulcrum Therapeutics Inc Recent Development
Table 161. Galapagos NV Corporation Information
Table 162. Galapagos NV Description and Major Businesses
Table 163. Galapagos NV Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 164. Galapagos NV Product
Table 165. Galapagos NV Recent Development
Table 166. Genethon SA Corporation Information
Table 167. Genethon SA Description and Major Businesses
Table 168. Genethon SA Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 169. Genethon SA Product
Table 170. Genethon SA Recent Development
Table 171. GTx Inc Corporation Information
Table 172. GTx Inc Description and Major Businesses
Table 173. GTx Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 174. GTx Inc Product
Table 175. GTx Inc Recent Development
Table 176. Santhera Pharmaceuticals Holding AG Corporation Information
Table 177. Santhera Pharmaceuticals Holding AG Description and Major Businesses
Table 178. Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 179. Santhera Pharmaceuticals Holding AG Product
Table 180. Santhera Pharmaceuticals Holding AG Recent Development
Table 181. Sarepta Therapeutics Inc Corporation Information
Table 182. Sarepta Therapeutics Inc Description and Major Businesses
Table 183. Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 184. Sarepta Therapeutics Inc Product
Table 185. Sarepta Therapeutics Inc Recent Development
Table 186. SOM Biotech SL Corporation Information
Table 187. SOM Biotech SL Description and Major Businesses
Table 188. SOM Biotech SL Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 189. SOM Biotech SL Product
Table 190. SOM Biotech SL Recent Development
Table 191. Strykagen Corp Corporation Information
Table 192. Strykagen Corp Description and Major Businesses
Table 193. Strykagen Corp Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 194. Strykagen Corp Product
Table 195. Strykagen Corp Recent Development
Table 196. Summit Therapeutics Plc Corporation Information
Table 197. Summit Therapeutics Plc Description and Major Businesses
Table 198. Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 199. Summit Therapeutics Plc Product
Table 200. Summit Therapeutics Plc Recent Development
Table 201. Taiho Pharmaceutical Co Ltd Corporation Information
Table 202. Taiho Pharmaceutical Co Ltd Description and Major Businesses
Table 203. Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 204. Taiho Pharmaceutical Co Ltd Product
Table 205. Taiho Pharmaceutical Co Ltd Recent Development
Table 206. Teijin Pharma Ltd Corporation Information
Table 207. Teijin Pharma Ltd Description and Major Businesses
Table 208. Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 209. Teijin Pharma Ltd Product
Table 210. Teijin Pharma Ltd Recent Development
Table 211. WAVE Life Sciences Ltd Corporation Information
Table 212. WAVE Life Sciences Ltd Description and Major Businesses
Table 213. WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 214. WAVE Life Sciences Ltd Product
Table 215. WAVE Life Sciences Ltd Recent Development
Table 216. Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 217. Global Duchenne Muscular Dystrophy Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 218. Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 219. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 220. North America: Duchenne Muscular Dystrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 221. North America: Duchenne Muscular Dystrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 222. Europe: Duchenne Muscular Dystrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 223. Europe: Duchenne Muscular Dystrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 224. Asia Pacific: Duchenne Muscular Dystrophy Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 225. Asia Pacific: Duchenne Muscular Dystrophy Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 226. Latin America: Duchenne Muscular Dystrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 227. Latin America: Duchenne Muscular Dystrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 228. Middle East and Africa: Duchenne Muscular Dystrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 229. Middle East and Africa: Duchenne Muscular Dystrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 230. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 231. Key Challenges
Table 232. Market Risks
Table 233. Main Points Interviewed from Key Duchenne Muscular Dystrophy Drugs Players
Table 234. Duchenne Muscular Dystrophy Drugs Customers List
Table 235. Duchenne Muscular Dystrophy Drugs Distributors List
Table 236. Research Programs/Design for This Report
Table 237. Key Data Information from Secondary Sources
Table 238. Key Data Information from Primary Sources
List of Figures
Figure 1. Duchenne Muscular Dystrophy Drugs Product Picture
Figure 2. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Development & Drug Target Product Picture
Figure 4. Mechanism of Action (MoA) Product Picture
Figure 5. Route of Administration (RoA) Product Picture
Figure 6. Molecule Type Product Picture
Figure 7. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Application in 2020 & 2026
Figure 8. Hospitals and Clinics
Figure 9. Medical Laboratories
Figure 10. Others
Figure 11. Duchenne Muscular Dystrophy Drugs Report Years Considered
Figure 12. Global Duchenne Muscular Dystrophy Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Duchenne Muscular Dystrophy Drugs Sales 2015-2026 (K Units)
Figure 14. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Region in 2019
Figure 17. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Region in 2019
Figure 19. Global Duchenne Muscular Dystrophy Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2019
Figure 21. Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Type in 2019
Figure 24. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type in 2019
Figure 26. Global Duchenne Muscular Dystrophy Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Application in 2019
Figure 29. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application in 2019
Figure 31. North America Duchenne Muscular Dystrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 32. North America Duchenne Muscular Dystrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Country in 2019
Figure 34. North America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country in 2019
Figure 35. U.S. Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 36. U.S. Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 38. Canada Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Duchenne Muscular Dystrophy Drugs Market Share by Type in 2019
Figure 40. North America Duchenne Muscular Dystrophy Drugs Market Share by Application in 2019
Figure 41. Europe Duchenne Muscular Dystrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 42. Europe Duchenne Muscular Dystrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Country in 2019
Figure 44. Europe Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country in 2019
Figure 45. Germany Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 46. Germany Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 48. France Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 50. U.K. Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 52. Italy Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 54. Russia Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Duchenne Muscular Dystrophy Drugs Market Share by Type in 2019
Figure 56. Europe Duchenne Muscular Dystrophy Drugs Market Share by Application in 2019
Figure 57. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 58. Asia Pacific Duchenne Muscular Dystrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Region in 2019
Figure 60. Asia Pacific Duchenne Muscular Dystrophy Drugs Revenue Market Share by Region in 2019
Figure 61. China Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 62. China Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 64. Japan Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 66. South Korea Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 68. India Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 70. Australia Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 72. Taiwan Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 74. Indonesia Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 76. Thailand Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 78. Malaysia Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 80. Philippines Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 82. Vietnam Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Share by Type in 2019
Figure 84. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Share by Application in 2019
Figure 85. Latin America Duchenne Muscular Dystrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 86. Latin America Duchenne Muscular Dystrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Duchenne Muscular Dystrophy Drugs Sales Market Share by Country in 2019
Figure 88. Latin America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country in 2019
Figure 89. Mexico Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 90. Mexico Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 92. Brazil Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 94. Argentina Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Duchenne Muscular Dystrophy Drugs Market Share by Type in 2019
Figure 96. Latin America Duchenne Muscular Dystrophy Drugs Market Share by Application in 2019
Figure 97. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 98. Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country in 2019
Figure 101. Turkey Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 102. Turkey Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 104. Saudi Arabia Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Duchenne Muscular Dystrophy Drugs Sales Growth Ra

---